LRRK2: Cause, Risk, and Mechanism
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In 2004 it was first shown that mutations in LRRK2 can cause Parkinson's disease. This initial discovery was quickly followed by the observation that a single particular mutation is a relatively common cause of Parkinson's disease across varied populations. Further genetic investigation has revealed a variety of genetic ties to Parkinson's disease across this gene. These include common alleles with quite broad effects on risk, likely through both alterations at the protein sequence level, and in the context of expression. A great deal of functional characterization of LRRK2 and disease-causing mutations in this protein has occurred over the last 9 years, and considerable progress has been made. Particular attention has been paid to the kinase activity of LRRK2 as a therapeutic target, and while it is no means certain that this is viable target it is likely that this hypothesis will be tested in clinical trials sooner rather than later. We believe that the future goals for LRRK2 research are, while challenging, relatively clear and that the next 10 years of research promises to be perhaps more exciting than the last.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., & Manolio, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903103106 · Cited by 4,013
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“While there has been recent success in the identification of this type of risk variant in Alzheimer’ disease [90, 91], the identification of such variants is challenging.”
BackgroundSelf-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“While there has been recent success in the identification of this type of risk variant in Alzheimer’ disease [90, 91], the identification of such variants is challenging.”
BackgroundFranke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228
Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain
Gibbs, J. R., van der Brug, M. P., Hernandez, D. G., Traynor, B. J., Nalls, M. A., Lai, S.-L., Arepalli, S., Dillman, A., Rafferty, I. P., Troncoso, J., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000952 · Cited by 769 · cited 1×
“It is reasonable to assume that non-coding variants exert their effect through mediating expression of proximal transcripts, and good evidence exists to support this idea [88]; to date there is not compelling evidence of such an association for the LRRK2 risk alleles.”
BackgroundSelf-citation(2007) · YUHSpace (Yonsei University Medical Library) · doi:10.1016/s1474 · Cited by 641
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619 · cited 1×
“One of the few consistent aspects of LRRK2 mutations in a cellular context is that they display increased toxicity compared to the wild type protein, and this toxicity is dependent upon kinase activity [108, 115].”
BackgroundInterplay of LRRK2 with chaperone-mediated autophagy
Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588 · cited 1×
“A more recent study has implicated LRRK2 in chaperone-mediated autophagy (CMA), suggesting that alterations in LRRK2 can result in defective CMA [142].”
BackgroundLRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
LRRK2 kinase in Parkinson's disease
Alessi, D. R., & Sammler, E. (2018) · Science · doi:10.1126/science.aar5683 · Cited by 345
Olfactory Dysfunction in Neurodegenerative Diseases
Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., Hummel, T., & Mullol, J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0796-4 · Cited by 274
Progress in unraveling the genetic etiology of Parkinson disease in a genomic era
Verstraeten, A., Theuns, J., & Van Broeckhoven, C. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.01.004 · Cited by 226
LRRK2 links genetic and sporadic Parkinson's disease
Kluss, J. H., Mamais, A., & Cookson, M. R. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180462 · Cited by 221
Metadata
- Authors
- Paisán-Ruiz, C., Lewis, P. A., & Singleton, A. B.
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2013-01-01
- Volume
- 3
- Issue
- 2
- Pages
- 85-103
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- OpenAlex
- W1611134798
- Cited by
- 151
- References
- 11
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LRRK2: Cause, Risk, and Mechanism. https://app.cochat.ai/papers/10.3233/jpd-130192
- The paper
- Paisán-Ruiz, C., Lewis, P. A., & Singleton, A. B. (2013). LRRK2: Cause, Risk, and Mechanism. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-130192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.